Enhertu® (fam-trastuzumab deruxtecan-nxki) has won FDA approval to treat unresectable or metastatic HER2-low breast cancer in adults who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

• This is the first FDA approved targeted therapy for HER2-low metastatic breast cancer.
• First FDA approved in 2019, Enhertu is also indicated to treat certain adults who have HER2- positive breast cancer or HER2-positive gastric or gastroesophageal junction adenocarcinoma.
• Recommended dosing for breast cancer is 5.4mg/kg of the patient’s body weight given as an intravenous infusion once every three weeks until disease progression or unacceptable toxicity occur.